Acquiring a unit of privately held Synnovation Therapeutics hands Novartis a prospect that might improve on medicines that, like its own Piqray, target tumors driven to growth by PIK3CA mutations.

Longevity is being framed as a consumer movement when, in reality, it is a pharmaceutical pipeline challenge. And pharma isn’t treating it like one yet.

Proposed acquisition supports the Novartis oncology strategy in hormone receptor positive, human epidermal growth factor receptor two-negative (HR+/HER2-) breast cancer The lead asset, SNV4818, ...

Swiss pharma giant Novartis is to pay up to $3bn to Synnovation Therapeutics to acquire a promising breast-cancer treatment that has shown to reduce the unwanted side effects of available medicines.

A federal judge in Oregon ruled on Thursday that Health Secretary Robert F. Kennedy Jr. had overstepped his legal authority when he declared in December that providers of gender-transition medical ...

FDA approval of CARDAMYST represents first new option in 30 years for the more than two million patients with PSVTParticipants using CARDAMYST in ...

Cervical cancer is a serious health issue that affects women worldwide. Cervical cancer is the cancer of the lower end of the uterus, known as the cervix. It is primarily caused by a virus called ...

SHE’S a millionaire businesswoman with the world at her feet but Rachel Watkyn is only too aware that health battles can ...

As cancer treatments become more advanced and personalized, survival rates for breast and brain cancers continue to rise. With more patients living ...

Get ready for a rare working weekend in the Senate with no break in sight. Majority Leader John Thune is keeping senators at ...

The Trust says the ranking 'reflects the scale of challenges which the organisation has been managing' ...

Novartis AG agreed to buy an experimental breast cancer drug from Synnovation Therapeutics for as much as $3 billion in a push to bolster its oncology pipeline.